-
公开(公告)号：US08697664B2
公开(公告)日：2014-04-15
申请号：US12708022
申请日：2010-02-18
申请人： Naomi Laing , Jaspal Singh Kang , Ian Foltz , Gadi Gazit-Bornstein , Xiao-Dang Yang , Sue A. Cartlidge , David Charles Blakey
发明人： Naomi Laing , Jaspal Singh Kang , Ian Foltz , Gadi Gazit-Bornstein , Xiao-Dang Yang , Sue A. Cartlidge , David Charles Blakey
CPC分类号： C07K16/2863 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.
摘要翻译： 本文公开了针对抗原PDGFR-α的靶向结合剂及其用途。 更具体地，本发明涉及针对抗原PDGFR-α的完全人单克隆抗体以及这些抗体的用途。 本发明的方面还涉及表达这种抗体的杂交瘤或其它细胞系。 所描述的靶向结合剂和抗体可用作诊断和治疗与PDGFR-α的活性和/或过度表达相关的疾病。
-
公开(公告)号：US07754859B2
公开(公告)日：2010-07-13
申请号：US11833473
申请日：2007-08-03
申请人： Naomi Laing , Jaspal Singh Kang , Ian Foltz , Gadi Gazit-Bornstein , Xiao-Dang Yang , David Charles Blakey , Sue A. Cartlidge
发明人： Naomi Laing , Jaspal Singh Kang , Ian Foltz , Gadi Gazit-Bornstein , Xiao-Dang Yang , David Charles Blakey , Sue A. Cartlidge
CPC分类号： C07K16/2863 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.
摘要翻译： 本文公开了针对抗原PDGFR-α的靶向结合剂及其用途。 更具体地，本发明涉及针对抗原PDGFR-α的完全人单克隆抗体以及这些抗体的用途。 本发明的方面还涉及表达这种抗体的杂交瘤或其它细胞系。 所描述的靶向结合剂和抗体可用作诊断和治疗与PDGFR-α的活性和/或过度表达相关的疾病。
-
3.发明申请公开(公告)号：US20090324601A1
公开(公告)日：2009-12-31
申请号：US12376052
申请日：2007-08-02
申请人： David Charles Blakey , Susan Ann Cartlidge , Ian Foltz , Jaspal Singh Kang , Laura Taylor , Gadi Gazit-Bornstein , Naomi Laing
发明人： David Charles Blakey , Susan Ann Cartlidge , Ian Foltz , Jaspal Singh Kang , Laura Taylor , Gadi Gazit-Bornstein , Naomi Laing
CPC分类号： C07K16/2863 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.
摘要翻译： 本文公开了针对抗原PDGFR-α的靶向结合剂及其用途。 更具体地，本发明涉及针对抗原PDGFR-α的完全人单克隆抗体以及这些抗体的用途。 本发明的方面还涉及表达这种抗体的杂交瘤或其它细胞系。 所描述的靶向结合剂和抗体可用作诊断和治疗与PDGFR-α的活性和/或过度表达相关的疾病。
-
4.发明申请TARGETED BINDING AGENTS DIRECTED TO SONIC HEDGEHOG HOMOLOG AND USES THEREOF 失效针对SONIC HEDGEHOG HOMOLOG的针对性绑定代理及其用途公开(公告)号：US20100196388A1
公开(公告)日：2010-08-05
申请号：US12562435
申请日：2009-09-18
申请人： David Jenkins , Neil Michaud , Naomi Laing , Jaspal Singh Kang
发明人： David Jenkins , Neil Michaud , Naomi Laing , Jaspal Singh Kang
IPC分类号： A61K39/395 , C07K16/18 , C07H21/04 , A61P35/00
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The invention relates to targeted binding agents against human sonic hedgehog homolog (Shh) and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to Shh. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of Shh and as diagnostics.
摘要翻译： 本发明涉及针对人类声波刺猬蛋白同源物（Shh）的靶向结合剂及其用途。 更具体地，本发明涉及针对Shh的完全人单克隆抗体。 所描述的靶向结合剂可用于治疗与Shh的活性和/或过量产生相关的疾病和作为诊断。
-
5.发明授权Targeted binding agents directed to sonic hedgehog homolog and uses thereof 失效针对声音刺猬蛋白同源物的靶向结合剂及其用途公开(公告)号：US08569459B2
公开(公告)日：2013-10-29
申请号：US13478580
申请日：2012-05-23
申请人： David Jenkins , Neil Michaud , Naomi Laing , Jaspal Singh Kang
发明人： David Jenkins , Neil Michaud , Naomi Laing , Jaspal Singh Kang
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The invention relates to targeted binding agents against human sonic hedgehog homolog (Shh) and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to Shh. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of Shh and as diagnostics.
摘要翻译： 本发明涉及针对人类声波刺猬蛋白同源物（Shh）的靶向结合剂及其用途。 更具体地，本发明涉及针对Shh的完全人单克隆抗体。 所描述的靶向结合剂可用于治疗与Shh的活性和/或过量产生相关的疾病和作为诊断。
-
6.发明申请TARGETED BINDING AGENTS DIRECTED TO SONIC HEDGEHOG HOMOLOG AND USES THEREOF 失效针对SONIC HEDGEHOG HOMOLOG的针对性绑定代理及其用途公开(公告)号：US20120328625A1
公开(公告)日：2012-12-27
申请号：US13478580
申请日：2012-05-23
申请人： David Jenkins , Neil Michaud , Naomi Laing , Jaspal Singh Kang
发明人： David Jenkins , Neil Michaud , Naomi Laing , Jaspal Singh Kang
IPC分类号： C07K16/18 , A61K39/395 , A61P35/00 , C12N15/13
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The invention relates to targeted binding agents against human sonic hedgehog homolog (Shh) and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to Shh. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of Shh and as diagnostics.
摘要翻译： 本发明涉及针对人类声波刺猬蛋白同源物（Shh）的靶向结合剂及其用途。 更具体地，本发明涉及针对Shh的完全人单克隆抗体。 所描述的靶向结合剂可用于治疗与Shh的活性和/或过量产生相关的疾病和作为诊断。
-
7.发明授权Targeted binding agents directed to sonic hedgehog homolog and uses thereof 失效针对声音刺猬蛋白同源物的靶向结合剂及其用途公开(公告)号：US08207306B2
公开(公告)日：2012-06-26
申请号：US12562435
申请日：2009-09-18
申请人： David Jenkins , Neil Michaud , Naomi Laing , Jaspal Singh Kang
发明人： David Jenkins , Neil Michaud , Naomi Laing , Jaspal Singh Kang
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The invention relates to targeted binding agents against human sonic hedgehog homolog (Shh) and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to Shh. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of Shh and as diagnostics.
摘要翻译： 本发明涉及针对人类声波刺猬蛋白同源物（Shh）的靶向结合剂及其用途。 更具体地，本发明涉及针对Shh的完全人单克隆抗体。 所描述的靶向结合剂可用于治疗与Shh的活性和/或过量产生相关的疾病和作为诊断。
-
公开(公告)号：US07572444B2
公开(公告)日：2009-08-11
申请号：US11303608
申请日：2005-12-16
申请人： Ian Foltz , Chadwick King , Peter Koon Bong Ling , Jaspal Singh Kang , Kathy Manchulenko , Francine Chen , Caroline Darne Scatena , Bruce A. Keyt , Edwin Madison , Wayne R. Godfrey , Stanislaw K. Morkowski , Jennifer H. Richardson
发明人： Ian Foltz , Chadwick King , Peter Koon Bong Ling , Jaspal Singh Kang , Kathy Manchulenko , Francine Chen , Caroline Darne Scatena , Bruce A. Keyt , Edwin Madison , Wayne R. Godfrey , Stanislaw K. Morkowski , Jennifer H. Richardson
IPC分类号： A61K39/395 , A61K51/00 , C07H21/04 , C12N5/06 , C12P21/06
CPC分类号： C07K16/40 , C07K2317/732 , C07K2317/76 , C07K2317/92 , G01N33/57492 , G01N2500/04
摘要： Binding proteins, such as fully human monoclonal antibodies and fragments thereof, directed to the antigen Matriptase and uses of such binding proteins are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising heavy and light chain immunoglobulin molecules capable of binding to Matriptase are also disclosed. The invention also discloses cell lines expressing such immunoglobulin molecules and monoclonal antibodies to Matriptase. The antibodies can be used to detect, prevent, and treat diseases such as cancer.
摘要翻译： 公开了涉及抗原Matriptase的结合蛋白，例如完全人单克隆抗体及其片段，以及这些结合蛋白的用途。 还公开了编码和包含能够结合Matriptase的重链和轻链免疫球蛋白分子的氨基酸序列的核苷酸序列。 本发明还公开了表达这种免疫球蛋白分子的细胞系和对Matriptase的单克隆抗体。 抗体可用于检测，预防和治疗诸如癌症的疾病。
-
公开(公告)号：US20140314784A1
公开(公告)日：2014-10-23
申请号：US14232751
申请日：2012-07-19
申请人： Vahe Bedian , Youzhen Wang , Ian Foltz , Palaniswami Rathanaswami , Jaspal Singh Kang , Adeela Kamal , Philipp Steiner
发明人： Vahe Bedian , Youzhen Wang , Ian Foltz , Palaniswami Rathanaswami , Jaspal Singh Kang , Adeela Kamal , Philipp Steiner
IPC分类号： C07K16/28 , A61K45/06 , A61K39/395
CPC分类号： C07K16/2866 , A61K39/3955 , A61K45/06 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
摘要： The disclosure relates to antibodies or antigen binding fragments that specifically bind to CXCR4 and inhibit the biological activity of CXCR4 and uses of such agents. More specifically the disclosure relates to fully human antibodies or antigen binding fragments directed to CXCR4 that specifically bind to CXCR4 and uses of these antibodies. Aspects of the disclosure also relate to hybridomas or other cell lines expressing such antibodies. The disclosed antibodies (including antigen binding fragments) are useful as diagnostics and for the treatment of diseases associated with the activity and/or expression of CXCR4.
摘要翻译： 本公开涉及特异性结合CXCR4并抑制CXCR4的生物学活性的抗体或抗原结合片段以及这些试剂的用途。 更具体地，本公开涉及针对CXCR4的完全人抗体或抗原结合片段，其特异性结合CXCR4和这些抗体的用途。 本公开的方面还涉及表达这种抗体的杂交瘤或其它细胞系。 所公开的抗体（包括抗原结合片段）可用作诊断和治疗与CXCR4的活性和/或表达相关的疾病。
-
公开(公告)号：US20120107324A1
公开(公告)日：2012-05-03
申请号：US13141608
申请日：2009-12-21
申请人： Catherine Anne Eberlein , Ian Foltz , Jaspal Singh Kang , Jane Kendrew , Avril Alfred , Simon Thomas Barry
发明人： Catherine Anne Eberlein , Ian Foltz , Jaspal Singh Kang , Jane Kendrew , Avril Alfred , Simon Thomas Barry
IPC分类号： A61K39/395 , C07K14/435 , C07K16/00 , A61P35/00 , C12N15/62 , C12N5/10 , C12P21/08 , C07K5/08 , C07H21/04
CPC分类号： B01F5/0619 , B01F5/0613 , B01F5/0617 , B01F15/00935 , B01F2005/0639
摘要： The invention relates to targeted binding agents against α5β1 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to α5β1. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of α5β1 and as diagnostics.
摘要翻译： 本发明涉及针对α5和bgr的靶向结合剂及其用途。 更具体地，本发明涉及针对α5和bgr的完全人单克隆抗体。 所描述的靶向结合剂可用于治疗与α5和bgr1的活性和/或过度产生相关的疾病和作为诊断。
-
-
-
-
-
-
-
-
-
搜索结果
30 条记录 (耗时 0.058 秒)
